

Jonatan Salzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6800191/publications.pdf>

Version: 2024-02-01

43
papers

2,057
citations

394421

19
h-index

276875

41
g-index

43
all docs

43
docs citations

43
times ranked

2513
citing authors

#	ARTICLE	IF	CITATIONS
1	Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. <i>JAMA Neurology</i> , 2020, 77, 184.	9.0	342
2	Rituximab in multiple sclerosis. <i>Neurology</i> , 2016, 87, 2074-2081.	1.1	278
3	Vitamin D as a protective factor in multiple sclerosis. <i>Neurology</i> , 2012, 79, 2140-2145.	1.1	192
4	Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. <i>Annals of Neurology</i> , 2016, 79, 950-958.	5.3	190
5	Neurofilament light as a prognostic marker in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 287-292.	3.0	162
6	Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 320.	9.0	155
7	Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. <i>Annals of Neurology</i> , 2020, 87, 688-699.	5.3	86
8	Smoking as a risk factor for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1022-1027.	3.0	54
9	Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1587-1591.	3.0	49
10	Erratum. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 70-73.	2.1	47
11	Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. <i>Lancet Neurology</i> , The, 2022, 21, 693-703.	10.2	45
12	Rituximab in paediatric onset multiple sclerosis: a case series. <i>Journal of Neurology</i> , 2016, 263, 322-326.	3.6	42
13	Vitamin D and axonal injury in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1027-1031.	3.0	39
14	Season of birth and multiple sclerosis in Sweden. <i>Acta Neurologica Scandinavica</i> , 2010, 121, 20-23.	2.1	38
15	Vitamin D and multiple sclerosis-from epidemiology to prevention. <i>Acta Neurologica Scandinavica</i> , 2015, 132, 56-61.	2.1	30
16	Vitamin A and systemic inflammation as protective factors in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1046-1051.	3.0	28
17	Dizziness and the Acute Vestibular Syndrome at the Emergency Department: A Population-Based Descriptive Study. <i>European Neurology</i> , 2018, 79, 5-12.	1.4	28
18	Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. <i>European Journal of Neurology</i> , 2019, 26, 1060-1067.	3.3	27

#	ARTICLE	IF	CITATIONS
19	Discontinuation and dose reduction of rituximab in relapsing/remitting multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 2161-2168.	3.6	21
20	Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis—a presymptomatic case-control study. <i>European Journal of Neurology</i> , 2021, 28, 3072-3079.	3.3	20
21	Vitamin D and multiple sclerosis: where do we go from here?. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 9-18.	2.8	19
22	The interaction between smoking and Epstein-Barr virus as multiple sclerosis risk factors may depend on age. <i>Multiple Sclerosis Journal</i> , 2014, 20, 747-750.	3.0	19
23	Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1814-1822.	3.0	19
24	Increasing prevalence of multiple sclerosis in Västernorrland County of Sweden. <i>Acta Neurologica Scandinavica</i> , 2015, 132, 389-394.	2.1	16
25	CSF neurofilament light. <i>Neurology</i> , 2016, 87, 1068-1069.	1.1	16
26	Radiological markers of idiopathic normal pressure hydrocephalus: Relative comparison of their diagnostic performance. <i>Journal of the Neurological Sciences</i> , 2020, 408, 116581.	0.6	15
27	Prevention of post-dural puncture headache: a randomized controlled trial. <i>European Journal of Neurology</i> , 2020, 27, 871-877.	3.3	15
28	Inflammatory activity and vitamin D levels in an MS population treated with rituximab. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731982659.	1.0	11
29	The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level—YES. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1239-1240.	3.0	7
30	The trials and tribulations of vitamin D: time for the “sunshine” vitamin to come in out of the cold or just more broken promises?. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 327-344.	2.4	6
31	Normative video head impulse test data in subjects with and without vascular risk factors. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 2619-2624.	1.6	6
32	Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: No. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1692-1693.	3.0	5
33	Variability of Normal Pressure Hydrocephalus Imaging Biomarkers with Respect to Section Plane Angulation: How Wrong a Radiologist Can Be?. <i>American Journal of Neuroradiology</i> , 2021, 42, 1201-1207.	2.4	5
34	Free vitamin D ₃ index and vitamin D-binding protein in multiple sclerosis: A presymptomatic case-control study. <i>European Journal of Neurology</i> , 2022, 29, 2335-2342.	3.3	5
35	Vitamin D and multiple sclerosis: timing of sampling, treatment and prevention. <i>Biomarkers in Medicine</i> , 2013, 7, 193-195.	1.4	4
36	Lumbar puncture preferences among Swedish neurologists. <i>Neurological Research</i> , 2015, 37, 92-94.	1.3	4

#	ARTICLE	IF	CITATIONS
37	Effectiveness of care in acute dizziness presentations. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 2389-2396.	1.6	4
38	Timing of cigarette smoking as a risk factor for multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2013, 6, 205-205.	3.5	3
39	MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study. <i>Neurology</i> , 2014, 83, 2099-2100.	1.1	2
40	How to minimize the risk for headache? A lumbar puncture practice questionnaire study = Hogyan csökkenthetők a posztpunkciós fejfájások kórtörténetes vizsgálata a lumbálpunkciós gyakorlatról. <i>Ideggyógyászati Szemle</i> , 2016, 69, 397-402.	0.7	2
41	Internet-based vestibular rehabilitation versus standard care after acute onset vertigo: a study protocol for a randomized controlled trial. <i>Trials</i> , 2022, 23, .	1.6	1
42	Maternal vitamin D status during pregnancy and bone-mineral content in offspring. <i>Lancet</i> , The, 2013, 382, 766-767.	13.7	0
43	Interaction Should Guide Management Decisions. <i>American Journal of Neuroradiology</i> , 2018, 39, E57-E57.	2.4	0